Equities Analysts Set Expectations for AXSM FY2025 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for Axsome Therapeutics in a report released on Monday, February 10th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($4.60) per share for the year, down from their prior forecast of ($4.30). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.70) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' FY2026 earnings at ($0.40) EPS.

AXSM has been the topic of a number of other research reports. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Truist Financial boosted their price objective on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. Leerink Partners boosted their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday, February 10th. Finally, Bank of America boosted their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and an average target price of $147.13.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock traded down $0.53 during mid-day trading on Thursday, reaching $131.15. 1,064,118 shares of the company's stock traded hands, compared to its average volume of 954,569. The company has a market cap of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05. The stock has a 50 day moving average of $97.84 and a two-hundred day moving average of $93.37. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $134.18.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AXSM. Creative Planning increased its holdings in Axsome Therapeutics by 29.8% in the 3rd quarter. Creative Planning now owns 10,854 shares of the company's stock worth $975,000 after buying an additional 2,489 shares during the period. Values First Advisors Inc. acquired a new position in Axsome Therapeutics in the 3rd quarter worth approximately $568,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after buying an additional 318 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in Axsome Therapeutics by 4.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 19,808 shares of the company's stock worth $1,780,000 after buying an additional 754 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Axsome Therapeutics by 65.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,232 shares of the company's stock worth $830,000 after buying an additional 3,652 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.